Strategic Focus Target Alzheimer’s-focused biotech buyers and CROs in early-stage to mid-stage trials, highlighting Telocyte’s telomerase therapy approach and FDA trial readiness to position as a partner for CNS aging interventions.

Clinical Readiness Leverage the plan for FDA-sponsored human trials to engage with regulatory consultants, contract research organizations, and biopharma sponsors seeking CNS disease trial collaborations, manufacturing, or translational services.

Funding Signals With reported revenue in the low-mid millions and a small team, position Telocyte as an agile, cost-effective partner for niche CNS biotech projects, offering tight integration with lean project teams and rapid decision cycles.

Tech & Ops Highlight cloud-based infrastructure and lightweight web presence as a gateway for enterprise partnerships, emphasizing scalable data management, secure collaboration, and digital marketing alignment to attract larger biomedical collaborators.

Market Positioning Differentiate from larger competitors by emphasizing a cure-focused narrative for Alzheimer’s, potential for disease modification, and strategic alliances with institutions pursuing telomere biology and CNS regeneration.